Enhanced antivirulent for antibiotic-resistant bacteria

Abstract

The teachings provided herein generally relate to enhanced antivirulents that inactivate antibiotic-resistant bacteria as opposed to relying on an antimicrobial killing of the bacteria, and the antivirulents are safe for oral administration. As such, the systems taught herein are valuable methods that provide an alternate pathway for treating a subject having an antibiotic-resistant bacterial infection.

We claim: 
     
         1 . A method of inhibiting virulence of a bacteria in the gastrointestinal tract of a subject comprising:
 administering an effective amount of a binding system to the subject, the binding system including:   an extract of a plant selected from the group consisting of Chinese gall, green tea, pomegranate, resveratrol, and combinations thereof; and,   hydrogen peroxide;   wherein the hydrogen peroxide is combined with the extract at a weight ratio that ranges from about 1:1000 to about 10:1 of an extract to the hydrogen peroxide.   
     
     
         2 . The method of  claim 1 , wherein the bacteria is an antibiotic resistant bacteria selected from a group consisting of  Escherichia   coli ,  Salmonella   enterica   serotype   typhimurium ,  Pseudomonas   aeruginosa ,  Pasteurella   multocida ,  Proteus   vulgaris ,  Klebsiella   pneumonia ,  Bordetella   bronchiseptica ,  Staphylococcus   aureus ,  methicillin   resistant   Staphylococcus   aureus  (MRSA),  Listeria   monocytogenes  and  Bacillus   cereus . 
     
     
         3 . The method of  claim 2 , wherein the bacteria is an antibiotic-resistant  Klebsiella   pneumonia . 
     
     
         4 . The method of  claim 2 , wherein the bacteria is an antibiotic-resistant  Salmonella   enterica   serotype   typhimurium . 
     
     
         5 . The method of  claim 2 , wherein the bacteria is an antibiotic-resistant  Pseudomonas   aeruginosa . 
     
     
         6 . The method of  claim 1 , further comprising:
 identifying the bacteria in the gastrointestinal system of a subject;   orally administering an effective amount of a composition to the subject, the composition comprising a combination of:
 an aqueous extract of pomegranate rind and an aqueous extract of green tea leaves; and, 
 a hydrogen peroxide; 
   wherein,
 the ratio of the extract to the hydrogen peroxide ranges from 1:2-1:20 (wt/wt); 
 the concentration of the composition ranges from 0.01 nM to 0.5M; and, 
 the combination inhibits the virulence of the bacteria in the subject by inactivating virulence factors in the bacteria without involving antibiotic resistance mechanisms. 
   
     
     
         7 . The method of  claim 6 , wherein the bacteria is an antibiotic resistant bacteria selected from a group consisting of  Escherichia   coli ,  Salmonella   enterica   serotype   typhimurium ,  Pseudomonas   aeruginosa ,  Pasteurella   multocida ,  Proteus   vulgaris ,  Klebsiella   pneumonia ,  Bordetella   bronchiseptica ,  Staphylococcus   aureus ,  methicillin   resistant   Staphylococcus   aureus   (MRSA) ,  Listeria   monocytogenes  and  Bacillus   cereus.   
     
     
         8 . The method of  claim 6 , wherein the bacteria is an antibiotic-resistant  Klebsiella   pneumonia . 
     
     
         9 . The method of  claim 6 , wherein the bacteria is an antibiotic-resistant  Salmonella   enterica   serotype   typhimurium . 
     
     
         10 . The method of  claim 6 , wherein the bacteria is an antibiotic-resistant  Pseudomonas   aeruginosa . 
     
     
         11 . A method of treating a subject having an antibiotic-resistant bacterial infection, comprising:
 identifying the antibiotic-resistant bacterial infection in the subject;   orally administering an effective amount of a composition to the subject having the antibiotic-resistant bacterial infection, the composition comprising a combination of:
 an aqueous extract of pomegranate rind and an aqueous extract of green tea leaves; and, 
 a hydrogen peroxide; 
   wherein,
 the ratio of the extract to the hydrogen peroxide ranges from 1:2-1:20 (wt/wt); 
 the concentration of the composition ranges from 0.01 nM to 0.5M; and, 
 the administering inhibits the virulence of the antibiotic resistant bacteria in the subject by inactivating virulence factors in the antibiotic-resistant bacteria without involving antibiotic resistance mechanisms. 
   
     
     
         12 . The method of  claim 11 , wherein the bacteria is an antibiotic resistant bacteria selected from a group consisting of  Escherichia   coli ,  Salmonella   enterica   serotype   typhimurium ,  Pseudomonas   aeruginosa ,  Pasteurella   multocida ,  Proteus   vulgaris ,  Klebsiella   pneumonia ,  Bordetella   bronchiseptica ,  Staphylococcus   aureus ,  methicillin   resistant   Staphylococcus   aureus   (MRSA) ,  Listeria   monocytogenes  and  Bacillus   cereus . 
     
     
         13 . The method of  claim 11 , wherein the bacteria is an antibiotic-resistant  Klebsiella   pneumonia . 
     
     
         14 . The method of  claim 11 , wherein the bacteria is an antibiotic-resistant  Salmonella   enterica   serotype   typhimurium . 
     
     
         15 . The method of  claim 11 , wherein the bacteria is an antibiotic-resistant  Pseudomonas   aeruginosa .